The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients.

M MüllerAtaru IgarashiK HashiguchiM KappelF PaoliniH YoshisueM FunakuboH SharmaM Okano

Published in: Journal of medical economics (2022)

Omalizumab could provide substantial benefits in terms of paid and unpaid work activities in patients with severe and most severe JCP. Our results also highlight the importance of considering unpaid work in estimating productivity costs due to poor health.

Keyphrases

end stage renal disease
early onset
climate change
ejection fraction
healthcare
newly diagnosed
public health
chronic kidney disease
peritoneal dialysis
prognostic factors
health information
risk assessment